Day: September 29, 2023

SAN FRANCISCO,, Sept. 29, 2023 (GLOBE NEWSWIRE) — The RealReal (the “Company” or “The RealReal”) (Nasdaq: REAL)—the world’s largest online marketplace for authenticated, resale luxury goods—today announced that Robert Julian will step down from his role as Chief Financial Officer (“CFO”) of the Company effective on the earlier of January 31, 2024 or the date a new CFO assumes the position. If a new CFO assumes the position prior to January 31, 2024, Mr. Julian will continue as an employee and serve as an executive advisor to the Company through January 31, 2024. To assist with the transition of his role, Mr. Julian has agreed to provide limited consulting services to the Company following his termination of employment from February 1, 2024 until June 30, 2024. The Board of Directors of the Company will retain an executive search...

Manila-based Animation Studio Profiled in 60-minute Program Detailing Creative Industry’s Role in Serving Global Audiences and Contributions to National Economy BOCA RATON, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) — Top Draw Animation (TDA), a leading source of premium animation production services for programming shown around the world, and a division of Grom Social Enterprises Inc. (NASDAQ: GROM), is featured in the recently-premiered Creative PH, a sixty-minute special examining the impact of creative industries on the Filipino economy and global audiences. The special, which premiered locally on CNN Philippines yesterday, was shared today by Top Draw Animation’s Executive Vice President, Jared Wolfson. The special’s segment on Top Draw Animation appears from (time codes) 14:47 through 28:23 here on CNN Philippines. For more information...

DENVER, Sept. 29, 2023 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces receipt of U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) for use with patients in the hospital intensive care unit (ICU) with acute or chronic systolic heart failure and worsening renal function due to cardiorenal syndrome or right ventricular dysfunction awaiting implantation of a left ventricular assist device (LVAD). The Breakthrough Device Designation is expected to expedite the clinical development and regulatory review of the SCD for use in this patient population. This is only the ninth Breakthrough...

Financial HighlightsGross Profit for the fourth fiscal quarter and fiscal 2023 increased $9.6 million, or 5%, and $79.2 million, or 9%, respectively, compared to the prior year periods. Margin per gallon for the fourth fiscal quarter and fiscal 2023 increased 10% and 12%, respectively, compared to the prior year periods. Net loss attributable to Ferrellgas Partners, L.P. was $29.1 million for the fourth fiscal quarter compared to a net loss of $19.4 million in the prior year period. Net earnings attributable to Ferrellgas Partners, L.P. was $136.9 million and $148.0 million for fiscal 2023 and 2022, respectively. Adjusted EBITDA for the fourth fiscal quarter decreased by $5.2 million, or 15%, compared to the prior year period. For fiscal 2023, Adjusted EBITDA increased by $20.1 million, or 6%, compared to fiscal 2022.Company HighlightsOn...

FREDERICK, Md., Sept. 29, 2023 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, is rolling out two new products, the SteraMist Hybrid and SteraMist Transport, to support its ongoing commitment to providing superior disinfection decontamination solutions for its growing customer base. SteraMist Hybrid An integral component of the SteraMist Environment System, SteraMist Hybrid is designed with capabilities to communicate with a facility.  The system is strategically positioned in a centralized location of the facility through a docking station and features our newly designed permanently mounted stainless steel applicators.  Recently, TOMI successfully installed the first SteraMist Hybrid at Indigo Pharmaceutical, Inc.’s existing...

Highlights include the company’s strong foundation for growth, focus on innovation and attractive long-term outlook SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, hosted its 2023 Investor R&D Day featuring presentations by Trey Martin, Chief Executive Officer, and other members of the Maravai leadership team that showcased the company’s strong foundation for growth, key differentiators, innovations, and attractive long-term growth outlook. “Maravai has established an exceptionally strong foundation and we are building momentum toward our long-term goal of achieving high teens revenue growth with expanding EBITDA margins,” said Trey Martin, CEO of Maravai...

JACKSONVILLE, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) — Regency Centers Corporation (The “Company”) (NASDAQ: REG) will announce its Third Quarter 2023 earnings results on Thursday, November 2, 2023, after the market closes. The Company’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website – investors.regencycenters.com. The Company will host an earnings conference call on Friday, November 3, 2023, at 11:00 a.m. ET.Third Quarter 2023 Earnings Conference CallDate: Friday, November 3, 2023Time: 11:00 a.m. ETDial#: 877-407-0789 or 201-689-8562Webcast: 3rd Quarter 2023 Webcast Link   Replay Webcast Archive: Investor Relations page under Webcasts & Presentations About Regency Centers Corporation (NASDAQ: REG) Regency Centers is a preeminent...

ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) dated August 29, 2023 regarding the Biologics License Application (BLA) for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. In the FDA’s recently issued CRL, although the Agency acknowledged the NORSE TWO pivotal trial met its safety and efficacy endpoints, it concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval...

-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application (BLA)- -Company On Track to Complete HOPE-3 Enrollment and Report Outcome from Interim Analysis in Q4 2023- -Conference Call and Webcast Today at 8:30 a.m. ET- SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced an update on the Company’s positive Type-B clinical meeting with the U.S. Food and Drug Administration (“FDA”) on the design and execution of HOPE-3, Capricor’s pivotal Phase 3 trial with lead asset CAP-1002 in treating Duchenne muscular dystrophy (“DMD”). Feedback from...

TORONTO, Sept. 29, 2023 (GLOBE NEWSWIRE) — APARTMENTLOVE INC. (CSE: APLV) (OTCQB: APMLF) (“ApartmentLove”, or the “Company”), a leading provider of online home, apartment and vacation rental marketing services to property managers, owners, renters and vacationers from around the world, is pleased to announce the signing of a share subscription agreement (the “Share Subscription Agreement”) between the Company and GEM Global Yield LLC SCS (“GGY”), a US$3.4 billion dollar alternative investment group with offices in New York, Paris and the Bahamas. The Share Subscription Agreement provides ApartmentLove the ability to draw multiple tranches (each, a “Draw Down”) of common shares (“Common Shares”) over the three-year term of the Share Subscription Agreement. Net proceeds received by the Company from the Share Subscription Agreement...